Figure 2. Risk ratios for seroconversion among patients with hematological malignancies compared with healthy controls after the first dose of the COVID-19 vaccine.
Figure 3. Risk ratios for seroconversion among patients with hematological malignancies compared with healthy controls after the second dose of the COVID-19 vaccine.